Fortress BiotechFBIO -8.61%44 Gross Margin % is 61.23% as of Mar. 2026, which is 9% below its 10-year median of 67.46. GuruFocus rates FBIO with a GF Score™ of 44/100 and a GF Value™ of $1.23 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 737 Biotechnology companies, Fortress Biotech ranks better than 56.04% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Fortress Biotech had a gross margin of 61.23% for the quarter that ended in Mar. 2026 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Fortress Biotech Gross Margin % Related Terms
Fortress Biotech Gross Margin % Historical Data
* Premium members only.
The historical data trend for Fortress Biotech's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FBIO vs PTHS, IBIO, NRXS: Gross Margin % Comparison
For the Biotechnology subindustry, Fortress Biotech's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fortress Biotech Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Fortress Biotech's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Fortress Biotech's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Fortress Biotech (FBIO) has a Gross Margin % of 61.23% as of Mar. 2026. Gross margin is the ratio of total gross profit to net sales. View historical data on Fortress Biotech and its competitors. This is near median its historical median of 67.46. Over the past decade, Fortress Biotech's Gross Margin % has ranged from 31.13 to 78.79. According to the industry distribution chart, Fortress Biotech ranks #324 out of 737 companies in the Biotechnology industry, placing it in the top 44%.
Is Fortress Biotech's Gross Margin % too high?
Fortress Biotech's current Gross Margin % of 61.23% is near median its 10-year median of 67.46. Over the past 10 years, this metric has ranged from a low of 31.13 to a high of 78.79. The Biotechnology industry median Gross Margin % is 60.92. Fortress Biotech's value of 61.23% is 0.5% above this industry median. Based on the distribution chart, Fortress Biotech ranks #324 out of 737 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Fortress Biotech has a GF Score™ of 44/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fortress Biotech's Gross Margin % compare to PTHS and IBIO?
According to the Biotechnology industry distribution chart, Fortress Biotech ranks #324 out of 737 companies for Gross Margin %. This puts Fortress Biotech in the upper half of its industry. The industry median Gross Margin % is 60.92. Fortress Biotech's value of 61.23% is 0.5% above this benchmark. Historically, Fortress Biotech's own Gross Margin % has ranged from 31.13 to 78.79 over the past decade. While the company's 10-year median is 67.46 vs. the industry median of 60.92, Fortress Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.92, based on 737 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fortress Biotech's current Gross Margin % of 61.23% is 0.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Fortress Biotech and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.92 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fortress Biotech's current Gross Margin % is 61.23%, which is near median its own 10-year median of 67.46. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fortress Biotech stock overvalued right now?
Based on GuruFocus' analysis, Fortress Biotech (FBIO) is currently considered Significantly Overvalued. The stock's GF Value™ is $1.23, compared to a current price of $2.76 — trading 124.4% above its estimated fair value. The current Gross Margin % is 61.23%, which is near median its 10-year median of 67.46 and 0.5% above the Biotechnology industry median of 60.92. Fortress Biotech's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Fortress Biotech (FBIO), the current Gross Margin % is 61.23% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fortress Biotech (FBIO) Overvalued in 2026?
Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued.
The current stock price of $2.76 is trading 124.4% above its estimated GF Value™ of $1.23.
GuruFocus considers Fortress Biotech to be Significantly Overvalued.
Key valuation signals for FBIO:
Gross Margin %: 61.23% (near median its 10-year median of 67.46)
GF Value™: $1.23 vs. price of $2.76 (124.4% above fair value)
Industry Position: 0.5% above the Biotechnology median (#324 of 737)
No single metric tells the full story. See the FBIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
44GF Score
Get the complete analysis for FBIO
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FBIO has been successfully added to your 
